How MAPS PBC Became Lykos Therapeutics and Raised $100M
01.12.2024 |
arrow_forward
Psychedelics Firm Gets $100 Million Makeover Led By Yale Dropout
01.10.2024 |
arrow_forward
Ecstasy-for-Medicine Advocate Raises $100 Million
01.10.2024 |
arrow_forward
MAPS Public Benefit Corporation Announces Oversubscribed Series A Financing and Renames to Lykos Therapeutics
01.05.2024 |
arrow_forward
MAPS Celebrates Submission of New Drug Application to FDA for MDMA-Assisted Therapy for PTSD
12.13.2023 |
arrow_forward
Shifting Strategy, MAPS Turns to Equity Investment
03.28.2023 |
arrow_forward
New Study Supports MDMA As A Treatment For PTSD
01.16.2023 |
arrow_forward
House Lawmakers Launch Bipartisan Psychedelics Caucus
11.21.2022 |
arrow_forward
National Psychotherapy Day: Creating Mass Mental Health for a Better World
09.25.2022 |
arrow_forward
‘How to Change Your Mind’: Taking a Trip With Michael Pollan
07.15.2022 |
arrow_forward
The Next Big Addiction Treatment
03.31.2022 |
arrow_forward
A Psychedelic May Soon Go to the FDA for Approval to Treat Trauma
02.01.2022 |
arrow_forward{"post_type":"post","orderby":"date","order":"DESC","posts_per_page":"12","category__in":""}